IP Group's Artios raises USD153 million for cancer therapy pipeline

(Alliance News) - IP Group PLC on Tuesday said portfolio company Artios Pharma Ltd recently ...

Alliance News 27 July, 2021 | 11:07AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - IP Group PLC on Tuesday said portfolio company Artios Pharma Ltd recently completed a USD153 million series C financing to fund its clinical-stage pipeline.

The FTSE 250-listed company noted that US-based medical investment companies Omega Funds and TCG X led the financing, in which both Novartis AG's Novartis Venture Fund and Pfizer Inc's Pfizer Ventures were new investors.

IP Group holds a 12% stake in Artios, with a fair value of GBP17.3 million at the end of 2020.

Artios develops cancer treatments aimed at repairing damaged DNA and has an active pipeline of cancer-therapies, IP Group said.

Pipeline candidates have been identified by a network of leading researchers in DNA damage response, including through Cancer Research UK, the investor noted.

This recent financing follows a USD84 million series B fundraise in August 2018.

"IP Group is reviewing the impact of the fundraising on the carrying value of the asset but does not anticipate a material change in its value," the company added.

Shares in IP Group were trading up 0.2% at 118.00 pence each in London on Tuesday afternoon.

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
IP Group PLC 48.85 GBX 3.39 -
Novartis AG 89.50 CHF -0.56
Pfizer Inc 25.40 USD 0.55

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures